New York, London, Bermuda, 29 October, 2007 - Celtic Pharmaceuticals Holdings L.P. (“Celtic Pharma”) today announced it has completed enrollment in a large Phase IIB clinical study in the US. Over 520 patients were recruited into the study in 10 weeks, significantly ahead of schedule. To date, more than half of the patients have already received the seven doses called for in the protocol and there has been a drop out rate of less than 10 percent.
